San Diego-primarily based Viking Therapeutics marked itself as a significant competitor during the weight loss drug industry in February following revealing promising data from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied being a weekly injection and in March the c